Paradromics is focused on developing advanced brain-computer interface (BCI) technologies, specifically through their product, the Connexus® Direct Data Interface (DDI). This innovative system is designed to facilitate high data-rate communication between the human brain and digital devices, enabling individuals with severe motor impairments—such as those caused by ALS, spinal cord injuries, or strokes—to communicate effectively. The DDI utilizes intracortical electrodes that provide precise, single-neuron resolution, allowing for the collection of rich neural signals directly from the brain. This capability is essential for translating neural activity into synthesized speech, text, and cursor control, thereby enhancing the independence and social connectivity of users.

The Connexus DDI is characterized by its scalability and user-friendly design, supporting over 1,600 intracortical channels for an industry-leading data rate. The system is built with proven materials, including titanium alloy and platinum-iridium electrodes, ensuring reliability and long-term implantation. Its architecture allows for real-time data processing through AI and machine learning, which interprets the user's intended actions. The DDI's design minimizes tissue disruption with fine electrodes and features a hermetically sealed structure to protect the electronics. As Paradromics continues to innovate, the DDI platform is expected to expand its capabilities, potentially benefiting millions of individuals with various neurological conditions.

United States

CONNECTING THE HUMAN BRAIN
What if we could restore or enhance function using the power of AI and advanced technology? Our direct data interface enables this connection.
MISSION
We are building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions. Our first clinical application will help severely motor-impaired people communicate, enabling social connection and restoring independence.
ABOUT
Paradromics was founded in 2015 by a team of engineers and neuroscientists, received early support from both NIH and DARPA, and is currently backed by venture capital.

Paradromics

Company Details